Гепаринотерапия при остром коронарном синдроме

Heparins in acute coronary syndrome (ACS) are used to prevent further coronary thrombogenesis, to eliminate hypercoag-ulation developing after thrombolysis, and to avert venous thrombopoiesis and systemic thromboembolisms. Heparins that are usually used in combination with antiaggregatory and thrombolytic agents are prescribed for the treatment of ACS. Both non-fractionated heparin (NFH) and low-molecular-weight heparins (LMWH), such as dalteparin, nadroparin, and enoxaparin, have been ascertained to have an effect. More and more preference is currently given to LMWH. The latter exert an independent positive effect on prognosis in patients with ACS, by reducing both the rate of mortality and that of myocardial re-infarctions approximately equally. On choosing a heparin, it is necessary to be first oriented to the renal function of a patient. The use of NFH, unlike that of LMWH, requires meticulous laboratory studies.